In Vitro Combination Effect of Topical and Oral Anti-Onychomycosis Drugs on Trichophyton rubrum and Trichophyton interdigitale
暂无分享,去创建一个
[1] E. Dannaoui,et al. Techniques for the Assessment of In Vitro and In Vivo Antifungal Combinations , 2021, Journal of fungi.
[2] Evy Ervianti,et al. COMBINATION ANTIFUNGAL THERAPY FOR ONYCHOMYCOSIS , 2018 .
[3] S. Poojary. Topical antifungals: A review and their role in current management of dermatophytoses , 2017 .
[4] Yoshiki Matsuda,et al. Efficacy Coefficients Determined Using Nail Permeability and Antifungal Activity in Keratin-Containing Media Are Useful for Predicting Clinical Efficacies of Topical Drugs for Onychomycosis , 2016, PloS one.
[5] N. Bhatia,et al. The Dermatologist’s Approach to Onychomycosis , 2015, Journal of fungi.
[6] A. Kaszuba,et al. Amorolfine vs. ciclopirox – lacquers for the treatment of onychomycosis , 2015, Postepy dermatologii i alergologii.
[7] J. Lear,et al. British Association of Dermatologists' guidelines for the management of onychomycosis 2014 , 2014, The British journal of dermatology.
[8] B. Elewski,et al. Tavaborole for the treatment of onychomycosis , 2014, Expert opinion on pharmacotherapy.
[9] K. Makimura,et al. In vitro susceptibility of dermatomycoses agents to six antifungal drugs and evaluation by fractional inhibitory concentration index of combined effects of amorolfine and itraconazole in dermatophytes , 2014, Microbiology and immunology.
[10] Bharti Bharti,et al. A study to compare efficacy of various oral antifungals (Fluconazole, Terbinafine, Itraconazole) in treatment of Onychomycosis , 2014 .
[11] Aditya K. Gupta,et al. Improved efficacy in onychomycosis therapy. , 2013, Clinics in dermatology.
[12] S. Botton,et al. Synergysm of voriconazole or itraconazole with other antifungal agents against species of Fusarium. , 2013, Revista iberoamericana de micologia.
[13] Y. Nishiyama,et al. Mechanism of Action of Efinaconazole, a Novel Triazole Antifungal Agent , 2013, Antimicrobial Agents and Chemotherapy.
[14] G. Petrikkos,et al. In vitro antifungal susceptibility of filamentous fungi causing rare infections: synergy testing of amphotericin B, posaconazole and anidulafungin in pairs. , 2012, The Journal of antimicrobial chemotherapy.
[15] Aditya K. Gupta,et al. New therapeutic options for onychomycosis , 2012, Expert opinion on pharmacotherapy.
[16] H. Korting,et al. Management of Onychomycoses , 1999, Drugs.
[17] K. Iozumi,et al. Epidemiological survey of foot diseases in Japan: Results of 30 000 foot checks by dermatologists , 2010, The Journal of dermatology.
[18] Yong-qiang Zhang,et al. Mechanism of the Synergistic Effect of Amiodarone and Fluconazole in Candida albicans , 2010, Antimicrobial Agents and Chemotherapy.
[19] Clinical,et al. Reference method for broth dilution antifungal susceptibility testing of filamentous fungi : Approved standard , 2008 .
[20] T. Peláez,et al. Synergistic Effect of Posaconazole and Caspofungin against Clinical Zygomycetes , 2007, Antimicrobial Agents and Chemotherapy.
[21] D. A. Santos,et al. In vitro antifungal oral drug and drug-combination activity against onychomycosis causative dermatophytes. , 2006, Medical mycology.
[22] S. Avner,et al. Combination of oral terbinafine and topical ciclopirox compared to oral terbinafine for the treatment of onychomycosis , 2005, The Journal of dermatological treatment.
[23] R Baran,et al. Topical antifungal drugs for the treatment of onychomycosis: an overview of current strategies for monotherapy and combination therapy , 2005, Journal of the European Academy of Dermatology and Venereology : JEADV.
[24] H. Maibach,et al. Progress on New Therapeuties for Fungal Nail Infections , 2005 .
[25] H. Ashbee,et al. Testing of antifungal combinations against yeasts and dermatophytes , 2004, The Journal of dermatological treatment.
[26] B. Sigurgeirsson,et al. Combination therapy for onychomycosis. , 2003, The British journal of dermatology.
[27] C B Moore,et al. In vitro interaction of terbinafine with itraconazole, fluconazole, amphotericin B and 5-flucytosine against Aspergillus spp. , 2002, The Journal of antimicrobial chemotherapy.
[28] M. Rinaldi,et al. In Vitro Activities of Terbinafine in Combination with Fluconazole, Itraconazole, Voriconazole, and Posaconazole against Clinical Isolates of Candida glabrata with Decreased Susceptibility to Azoles , 2002, Journal of Clinical Microbiology.
[29] C. Lynde,et al. Single-blind, randomized, prospective study on terbinafine and itraconazole for treatment of dermatophyte toenail onychomycosis in the elderly. , 2001, Journal of the American Academy of Dermatology.
[30] F. Müller,et al. Synergism of Voriconazole and Terbinafine against Candida albicans Isolates from Human Immunodeficiency Virus-Infected Patients with Oropharyngeal Candidiasis , 2001, Antimicrobial Agents and Chemotherapy.
[31] N S Ryder,et al. Synergistic interaction of terbinafine with triazoles or amphotericin B against Aspergillus species. , 2001, Medical mycology.
[32] A. Coquerel,et al. Pharmacokinetics of Antifungal Agents in Onychomycoses , 2001, Clinical pharmacokinetics.
[33] R. Summerbell,et al. Prevalence and epidemiology of onychomycosis in patients visiting physicians' offices: a multicenter canadian survey of 15,000 patients. , 2000, Journal of the American Academy of Dermatology.
[34] B. Elewski,et al. Onychomycosis: Pathogenesis, Diagnosis, and Management , 1998, Clinical Microbiology Reviews.
[35] L. Hansson. Rationale for combination therapy. , 1987, British journal of clinical pharmacology.